PIQ · ASX

Proteomics International Laboratories Ltd. (ASX:PIQ)

AU$0.36

 0.0 (0.0%)
ASX:Live
09/05/2025 02:39:25 PM
Recent Price downgrade Recent Earnings upgrade HALO Ords HALO Earnings Momentum GROWTH AUS +2
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PIQ Overview

PIQ Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Weak

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About PIQ

Website

N/A

Telephone

61.8.9389.1992

Address

QQ Block, Nedlands 6 Verdun Street QEII Medical Centre Perth, Western Australia (WA) 6009

Description

Proteomics International Laboratories Ltd. is a medical technology company which operates at the forefront of predictive diagnostics and bio-analytical services. The company was founded by Richard Lipscombe and Bill Parker in 2001 and is headquartered in Perth, Australia.

PIQ Price Chart

Key Stats

Market Cap

AU$52.47M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.35 - 1.12

Trade Value (12mth)

AU$35,417.00

1 week

-3.95%

1 month

-18.89%

YTD

-53.5%

1 year

-64.56%

All time high

1.48

Key Fundamentals

EPS 3 yr Growth

80.40%

EBITDA Margin

-916.60%

Operating Cashflow

-$6m

Free Cash Flow Return

-62.00%

ROIC

-70.70%

Interest Coverage

-352.80

Quick Ratio

10.10

Other Data

Shares on Issue (Fully Dilluted)

131m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.47

PIQ Announcements

Latest Announcements

Date Announcements

05 May 25

Share Purchase Plan Offer Booklet

×

Share Purchase Plan Offer Booklet

02 May 25

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

02 May 25

Correction - Notice of Extraordinary General Meeting/Proxy

×

Correction - Notice of Extraordinary General Meeting/Proxy

29 April 25

Application for quotation of securities - PIQ

×

Application for quotation of securities - PIQ

29 April 25

Notification regarding unquoted securities - PIQ

×

Notification regarding unquoted securities - PIQ

29 April 25

Notice Under Section 708A

×

Notice Under Section 708A

28 April 25

Options Prospectus

×

Options Prospectus

24 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

22 April 25

$4.5m placement to launch Promarker diagnostics

×

$4.5m placement to launch Promarker diagnostics

22 April 25

Proposed issue of securities - PIQ

×

Proposed issue of securities - PIQ

22 April 25

Proposed issue of securities - PIQ

×

Proposed issue of securities - PIQ

22 April 25

Proposed issue of securities - PIQ

×

Proposed issue of securities - PIQ

22 April 25

Proposed issue of securities - PIQ

×

Proposed issue of securities - PIQ

16 April 25

Pause in Trading

×

Pause in Trading

16 April 25

Trading Halt

×

Trading Halt

10 April 25

Investor Presentation - JMM Biotech Forum

×

Investor Presentation - JMM Biotech Forum

08 April 25

Investor Presentation Morgan Stanley Alpha ex-100 Conference

×

Investor Presentation Morgan Stanley Alpha ex-100 Conference

07 April 25

Proteomics appoints Clinical Advisory Board for PromarkerEso

×

Proteomics appoints Clinical Advisory Board for PromarkerEso

28 March 25

Australian patent granted for OxiDx oxidative stress test

×

Australian patent granted for OxiDx oxidative stress test

20 March 25

Investor Presentation - Broker Meets Biotech

×

Investor Presentation - Broker Meets Biotech

17 March 25

Response to ASX Aware Query

×

Response to ASX Aware Query

13 March 25

PromarkerD predictive test for DKD launched in Australia

×

PromarkerD predictive test for DKD launched in Australia

11 March 25

PromarkerD outperforms conventional tests--results published

×

PromarkerD outperforms conventional tests--results published

28 February 25

Proteomics opens CLIA certified reference laboratory in USA

×

Proteomics opens CLIA certified reference laboratory in USA

26 February 25

Interim Financial Report and Appendix 4D

×

Interim Financial Report and Appendix 4D

PIQ Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.05 -0.05 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.05 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -67.6 -12.5 4.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.06 -0.05 Lock Lock Lock
     Growth % Lock Lock Lock Lock -85.9 -15.1 14.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -3.7 -6.9 -5.4 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.03 0.07 0.07 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 0.07 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.6 115.8 3.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 106 116 126 Lock Lock Lock
Basic m Lock Lock Lock Lock 106 116 126 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.6 -51.0 22.2 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -5 -7 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -105.4 -35.7 -2.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -358.9 -993.2 -829.7 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 459 1,093 930 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -6 -8 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -56.7 -22.7 -6.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -421.1 -1,053.4 -916.6 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -7 -8 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.9 -22.9 -8.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -449.1 -1,125.9 -998.1 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -8 -9 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -5 -6 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -73.9 -24.2 -3.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -333.9 -845.7 -714.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -4 -6 -6 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 11 7 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -4 -7 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -52.0 -88.3 13.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -2.5 -9.5 -6.7 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 2 6 7 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 5 10 11 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -2 -6 -6 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 3 8 9 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 3 8 10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.4 147.9 14.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -92.2 -61.3 -58.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -146.5 -73.7 -67.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -120.8 -139.6 -99.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -90.4 -104.6 -70.7 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -64.3 -96.4 -62.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -2,328.8 N/A -352.8 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.3 0.8 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -62.2 -71.2 -67.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.6 7.6 10.1 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.6 7.6 10.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 48.4 72.4 72.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -208.0 -516.2 -618.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.8 0.3 0.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.6 0.1 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 34.7 21.1 6.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.1 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.1 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -448.9 -1,106.8 -968.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -123.9 -80.2 -79.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -92.2 -61.3 -58.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.6 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -146.5 -73.7 -67.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -146.5 -73.7 -67.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 459.6 1,076.3 931.8 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 459.6 1,076.3 931.8 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 17.6 15.3 4.7 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 442.0 1,060.9 927.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.47%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PIQ Shortsell

Frequently Asked Questions

The current share price of Proteomics International Laboratories Ltd. (PIQ:ASX) is AU$0.36.
The 52-week high share price for Proteomics International Laboratories Ltd. (PIQ:ASX) is AU$1.12.
The 52-week low share price for Proteomics International Laboratories Ltd. (PIQ:ASX)? is AU$0.35.
Proteomics International Laboratories Ltd. (PIQ:ASX) does not pay a dividend.
Proteomics International Laboratories Ltd. (PIQ:ASX) does not pay a dividend.
Proteomics International Laboratories Ltd. (PIQ:ASX) has a franking level of 0.0%.
Proteomics International Laboratories Ltd. (PIQ:ASX) is classified in the Healthcare.
The current P/E ratio for Proteomics International Laboratories Ltd. (PIQ:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.